EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia

Rathana Kim iD, Marie Passet, Hugo Bergugnat, Loïc Vasseur iD, Thibaut Leguay, Françoise Huguet, Mathilde Hunault, Tom Sexton, Melha Benlebna, Julie Renard, Emmanuel Raffoux, Cédric Pastoret und 18 weitere

HemaSphere · 2026-06 · 10 (6)

DOI: 10.1002/hem3.70383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 15.06.2026. Verfasst von Rathana Kim und 29 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Inserm UMR 1342, Institut de Recherche Saint-Louis (IRSL) Paris France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B‐cell acute lymphoblastic leukemia (B‐ALL) is a heterogeneous malignancy driven by diverse genetic alterations. Among these, CEBP family genes and ZEB2 are recurrently involved, yet the spectrum of genomic mechanisms and their clinical impact remain incompletely defined. Integrated genomic analyses of a cohort of 992 Philadelphia‐negative adult B‐ALL patients revealed multiple mechanisms of enhancer hijacking‐mediated deregulation of CEBPA , CEBPB , CEBPD , and CEBPE , including IGH and several non‐ IGH fusions, as well as noncoding mutations in regulatory regions. Combined with gene expression analysis, we identified three distinct subtypes, defined by co‐occurring CEBP and ZEB2 p.H1038R alterations (CEBP/ZEB2, n = 18 cases); isolated CEBP alterations (CEBPalt, n = 43), associated with frequent IKZF1 deletions and FLT3 deregulation; and isolated ZEB2 p.H1038R mutation (ZEB2alt, n = 15), associated with various additional genomic hits targeting ZEB2 and enhancing mutant ZEB2 expression. The three subtypes exhibited distinct clinical features, including age distribution (patients with CEBP/ZEB2 and ZEB2alt B‐ALL were younger) and sex bias (female and male predominance in CEBPalt and ZEB2alt, respectively). Early treatment responses and outcomes also differed: patients with CEBP/ZEB2 B‐ALL had a favorable early response, in contrast to patients with ZEB2alt B‐ALL, who had high levels of minimal residual disease and a dismal prognosis. Collectively, our findings define CEBP and ZEB2 alterations as drivers of genetically and clinically distinct subtypes of adult B‐ALL and provide a rationale for subtype‐specific risk stratification. Preclinical experiments in CEBPalt B‐ALL patient‐derived xenografts demonstrated sensitivity to FLT3 inhibition, highlighting a potential therapeutic vulnerability.

Autor:innen und Institutionen

  • Université Paris Cité, Inserm UMR 1342, Institut de Recherche Saint-Louis (IRSL) Paris France.
  • Laboratoire d'Hématologie AP-HP, hôpital Saint-Louis Paris France.
  • The Leukemia Institute Paris Saint-Louis Paris France.
  • Service d'Hématologie AP-HP, hôpital Saint-Louis Paris France.
  • Service d'Hématologie CHU de Bordeaux, hôpital du Haut-Levêque Pessac France.
  • Service d'Hématologie Institut Universitaire de Cancer Toulouse-Oncopole, CHU de Toulouse Toulouse France.

ORCID-Profile: Rathana Kim, Loïc Vasseur, Nicolas Duployez, Emmanuelle Clappier

Zitieren

APA

Kim, R., Passet, M., Bergugnat, H., Vasseur, L., Leguay, T., Huguet, F., Hunault, M., Sexton, T., Benlebna, M., Renard, J., Raffoux, E., Pastoret, C., Erb, C., Chat, L., Delabesse, E., Gachet, S., Bonmati, C., Balsat, M., Braun, T., …, & Clappier, E. (2026). CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70383

Vancouver

Kim R, Passet M, Bergugnat H, Vasseur L, Leguay T, Huguet F, et al. CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia. HemaSphere. 2026;10(6). doi:10.1002/hem3.70383

BibTeX
@article{Kim2026,
  author = {Kim, Rathana and Passet, Marie and Bergugnat, Hugo and Vasseur, Loïc and Leguay, Thibaut and Huguet, Françoise and Hunault, Mathilde and Sexton, Tom and Benlebna, Melha and Renard, Julie and Raffoux, Emmanuel and Pastoret, Cédric and Erb, Cathie and Chat, Laureen and Delabesse, Eric and Gachet, Stéphanie and Bonmati, Caroline and Balsat, Marie and Braun, Thorsten and Bidet, Audrey and Duployez, Nicolas and Graux, Carlos and Chalandon, Yves and Rousselot, Philippe and Chevallier, Patrice and Soulier, Jean and Lhéritier, Véronique and Dombret, Hervé and Boissel, Nicolas and Clappier, Emmanuelle},
  title = {CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1002/hem3.70383}
}
Kostenlos starten →